- Home
- CRVO vs PRLD Comparison
CRVO vs PRLD Comparison
Compare CRVO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- PRLD
- Stock Information
- Founded
- CRVO 2001
- PRLD 2016
- Country
- CRVO United States
- PRLD United States
- Employees
- CRVO N/A
- PRLD N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- CRVO Health Care
- PRLD Health Care
- Exchange
- CRVO Nasdaq
- PRLD Nasdaq
- Market Cap
- CRVO 65.2M
- PRLD 69.1M
- IPO Year
- CRVO N/A
- PRLD 2020
- Fundamental
- Price
- CRVO $7.58
- PRLD $1.49
- Analyst Decision
- CRVO Strong Buy
- PRLD Strong Buy
- Analyst Count
- CRVO 6
- PRLD 3
- Target Price
- CRVO $21.50
- PRLD $4.00
- AVG Volume (30 Days)
- CRVO 64.4K
- PRLD 3.4M
- Earning Date
- CRVO 11-10-2025
- PRLD 11-12-2025
- Dividend Yield
- CRVO N/A
- PRLD N/A
- EPS Growth
- CRVO N/A
- PRLD N/A
- EPS
- CRVO N/A
- PRLD N/A
- Revenue
- CRVO $6,159,786.00
- PRLD $10,500,000.00
- Revenue This Year
- CRVO N/A
- PRLD N/A
- Revenue Next Year
- CRVO N/A
- PRLD N/A
- P/E Ratio
- CRVO N/A
- PRLD N/A
- Revenue Growth
- CRVO N/A
- PRLD 250.00
- 52 Week Low
- CRVO $1.80
- PRLD $0.61
- 52 Week High
- CRVO $16.94
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- CRVO 54.12
- PRLD 49.53
- Support Level
- CRVO $6.56
- PRLD $1.17
- Resistance Level
- CRVO $7.80
- PRLD $1.62
- Average True Range (ATR)
- CRVO 0.46
- PRLD 0.38
- MACD
- CRVO 0.11
- PRLD -0.05
- Stochastic Oscillator
- CRVO 87.86
- PRLD 10.34
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.